Jpmorgan Chase & CO Foghorn Therapeutics Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Foghorn Therapeutics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 11,053 shares of FHTX stock, worth $89,197. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,053
Previous 14,038
21.26%
Holding current value
$89,197
Previous $94,000
32.98%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding FHTX
# of Institutions
72Shares Held
32.7MCall Options Held
6KPut Options Held
1.8K-
Flagship Pioneering Inc. Cambridge, MA12.7MShares$102 Million8.71% of portfolio
-
Bvf Inc San Francisco, CA5.3MShares$42.8 Million0.93% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY2.52MShares$20.3 Million0.3% of portfolio
-
Raymond James & Associates St Petersburg, FL2.3MShares$18.5 Million0.01% of portfolio
-
Euclidean Capital LLC New York, NY1.57MShares$12.7 Million1.14% of portfolio
About Foghorn Therapeutics Inc.
- Ticker FHTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,637,400
- Market Cap $336M
- Description
- Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-28...